



**This document is a postprint version of an article published in *Veterinary Microbiology* © Elsevier after peer review. To access the final edited and published work see <https://doi.org/10.1016/j.vetmic.2018.12.005>**

1 **Comparison of vaccination protocols against**

2 ***Mycoplasma hyopneumoniae* during the gilt acclimation period**

3 Laura Garza-Moreno<sup>1, 2</sup>, Maria Pieters<sup>3</sup>, Sergio López-Soria<sup>1</sup>,  
4 Marta Carmona<sup>2</sup>, Roman Krejci<sup>4</sup>, Joaquim Segalés<sup>5,6</sup>, Marina Sibila<sup>1,\*</sup>

---

5 <sup>1</sup>IRTA, Centre de Recerca en Sanitat Animal (CRESA, IRTA-UAB),  
6 Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra,  
7 Spain

8 <sup>2</sup>CEVA Salud Animal, Avenida Diagonal, 609-6015, 9<sup>a</sup> planta, 08028  
9 Barcelona, Spain

10 <sup>3</sup>Department of Veterinary Population Medicine and Veterinary  
11 Diagnostic Laboratory, College of Veterinary Medicine, University of  
12 Minnesota, St. Paul, MN 55108, United States

13 <sup>4</sup>CEVA Santé Animale, La Ballasteriere – BP 126, 33501, Libourne  
14 Cedex, France

15 <sup>5</sup>UAB, Centre de Recerca en Sanitat Animal (CRESA, IRTA-UAB),  
16 Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra,  
17 Spain

18 <sup>6</sup>Departament de Sanitat i Anatomia Animals, Facultat de Veterinària,  
19 UAB, 08193 Bellaterra Spain

20

---

21 Laura Garza-Moreno: [laura.garza@irta.cat](mailto:laura.garza@irta.cat)

22 Maria Pieters: [piet0094@umn.edu](mailto:piet0094@umn.edu)

23 Sergio López-Soria: [sergio.lopez@irta.cat](mailto:sergio.lopez@irta.cat)

24 Marta Carmona: [marta.carmona@ceva.com](mailto:marta.carmona@ceva.com)

25 Roman Krejci: [roman.krejci@ceva.com](mailto:roman.krejci@ceva.com)

26 Joaquim Segalés: [joaquim.segales@irta.cat](mailto:joaquim.segales@irta.cat)

27 Marina Sibila: [marina.sibila@irta.cat](mailto:marina.sibila@irta.cat)

28 \*corresponding author

29 **Keywords**

30 *Mycoplasma hyopneumoniae*; gilt acclimation; vaccination protocol; piglet colonization

31 **Abstract**

32 This study evaluated different gilt vaccination protocols against *Mycoplasma (M.)*  
33 *hyopneumoniae* at acclimation and their effect on the genetic diversity. A total of 180 *M.*  
34 *hyopneumoniae* naïve gilts were selected 1 week post-entry (wpe) at the acclimation barn  
35 in a clinically affected *M. hyopneumoniae* farm. Gilts were distributed according to the  
36 *M. hyopneumoniae* antibodies levels into three different vaccination schedules: A) four  
37 doses of a *M. hyopneumoniae* commercial vaccine at 2, 4, 6 and 8 wpe; B) two vaccine  
38 doses at 2 and 6 wpe and PBS at 4 and 8 wpe; and C) four PBS doses at the same wpe.  
39 Detection of *M. hyopneumoniae* (rt-PCR) and antibodies (ELISA) were assessed in gilts  
40 at 1, 14, 27 and 34 wpe and in 6 of their piglets at weaning. rt-PCR positive gilts were  
41 detected at 14 wpe, being the proportion significantly lower in groups A and B (3/120,  
42 3%) than C (27/60, 45%). Seroconversion was detected at 14 wpe, showing significant  
43 differences in percentage of inhibition (PI) between groups A (median 4.9, range 3.1-  
44 19.9) and B (5.5, 3.7-13.5), and C (14.3, 3.3-53.2). Gilts remained seropositive over the  
45 study; significant differences in PI were detected between groups A and B versus C.  
46 Piglets were rt-PCR negative; proportion of seropositive piglets coming from vaccinated  
47 gilts was significantly higher than the non-vaccinated group. *M. hyopneumoniae*  
48 characterization showed high variability. Hence, gilt vaccination with 2 or 4 doses  
49 significantly decreased the pathogen infectious pressure, variability, and provided high  
50 antibody levels to gilts and their offspring.

51

## 52 **1. Introduction**

53 *Mycoplasma hyopneumoniae* (*M. hyopneumoniae*) is the primary agent of enzootic  
54 pneumonia (EP), a chronic respiratory disease that affects mainly growing and finishing  
55 pigs. This disease is an important concern to the swine industry due to economic losses  
56 generated by a reduction of performance and growth, as well as antimicrobial treatments  
57 and control/eradication costs (Thacker and Minion, 2012).

58 *Mycoplasma hyopneumoniae* is transmitted by direct contact between infected and  
59 susceptible animals (Maes et al., 1996). Since intrauterine infection has not been  
60 described, piglets are considered *M. hyopneumoniae*-free at birth. Hence, the first  
61 exposure to *M. hyopneumoniae* would occur during the lactation period when piglets are  
62 in contact with a shedding dam (Sibila et al., 2007). Taking into account that piglet  
63 colonization at weaning has been correlated with *M. hyopneumoniae* prevalence and  
64 severity of lung lesions in growing-finishing pigs (Fano et al., 2007; Sibila et al., 2007), a  
65 reduction of transmission between dams and offspring during the lactation period,  
66 together with the piglet vaccination, seem to be a key point for disease control.  
67 Additionally, bacterial shedding of gilts and young sows seems to be higher than that of  
68 older parity sows (Boonsoongnern et al., 2012). Thus, an adequate gilt acclimation  
69 focused on decreasing the bacterial shedding at first farrowing should aid in reducing  
70 piglet colonization at weaning age (Pieters and Fano, 2016).

71 Information on gilt acclimation practices is limited. In Europe, a previous study based  
72 on a survey identified the vaccination against *M. hyopneumoniae* as the acclimation  
73 strategy most used by the participants (Garza-Moreno et al., 2017). Likewise, *M.*  
74 *hyopneumoniae* gilt vaccination has been described as the most common practice in US  
75 (Fano and Payne, 2015). Recently, a review compared the acclimation practices carried

76 out in Europe and America (Mexico and USA), being vaccination the main strategy used  
77 as well (Garza-Moreno et al., 2018).

78 Gilt vaccination schedules against *M. hyopneumoniae* can be variable among farms in  
79 terms of number of administered vaccine doses and application timings. Thus, gilt  
80 vaccination protocols based on multiple doses are becoming commonly used in some  
81 parts of the world (Alfonso et al., 2004; Yeske et al., 2007; Garza-Moreno et al., 2018).  
82 Nevertheless, no information regarding the efficacy of multiple gilt vaccination during  
83 the acclimation period is available in the literature. Therefore, this study aimed to  
84 compare different gilt vaccination schedules on the *M. hyopneumoniae* gilt  
85 seroconversion and shedding at different times post-vaccination, as well as piglet  
86 antibody detection and colonization at weaning. Moreover, this study also investigated  
87 the potential effect of vaccination on the genetic diversity of *M. hyopneumoniae* within  
88 the studied farm.

89

## 90 **2. Material and methods**

### 91 *2.1. Farm management and housing conditions*

92 A conventional *M. hyopneumoniae* positive, clinically affected (Garza-Moreno et al.,  
93 2018) farrow-to-finish farm introducing external negative and own positive replacement  
94 gilts was selected. The selected farm had a gilt development unit (GDU) for acclimation  
95 with a duration approximately of 10 weeks, which followed all-in/all-out management  
96 practices. After acclimation, external and own replacement gilt batches were moved to  
97 oestrus detection and synchronization unit (DSU) and were allocated sharing pens (60  
98 gilts per pen). At the DSU, gilt oestrus was synchronized and gilts were divided in  
99 weekly batches of 90 gilts according to oestrus detection time. Gilts were artificially  
100 inseminated at the second oestrus and pregnancy diagnosis was performed 4 weeks after

101 insemination. Once pregnancy was confirmed, pregnant gilts were moved to the gestation  
102 unit and housed in pens (60 gilts/pen). Finally, one week previous to delivery, gilts were  
103 moved to the farrowing units. In these facilities, with continuous flow and weekly batch  
104 management, a total of 50 gilts and sows of different parities were housed.

## 105 2.2. *M. hyopneumoniae* infectious status previous to the start of the study

106 To confirm *M. hyopneumoniae* gilt infection during acclimation, laryngeal swabs (LS)  
107 from a total of 20 gilts (10 gilts/batch) showing clinical signs of dry coughing from two  
108 previous batches of own replacement (FS1 and FS2) were collected at 14 weeks post-  
109 entry (wpe) in the GDU. In these samplings, 19 out of 20 (95%) gilts were *M.*  
110 *hyopneumoniae* positive by real-time PCR (rt-PCR), being 10 out of 10 (100%) positive  
111 gilts in FS1 and 9 out of 10 (90%) in FS2. The Ct values varied from 30.7 to 36.9 in FS1  
112 and from 27.5 to 36.9 in FS2.

## 113 2.3. *Animal selection and study design*

114 Blood samples (BS) and LS from a total of 180 six month-old gilts coming from an  
115 external *M. hyopneumoniae* negative farm were collected at 1 wpe at the GDU (Figure 1).  
116 Laryngeal swabs and BS were tested for detection of the pathogen and the antibodies  
117 against it, respectively. Afterwards, gilts were randomly divided into three groups (A:  
118 four vaccine doses; B: two vaccine doses and C: no vaccinated) balanced according to *M.*  
119 *hyopneumoniae* antibodies measured by ELISA percentage of inhibition (PI). Animals  
120 received intramuscularly 2 mL per dose of a *M. hyopneumoniae* commercial vaccine  
121 (Hyogen<sup>®</sup>, CEVA Santé Animale, Libourne, Cedex, France), indicated for pigs from 3  
122 weeks onwards, and/or 2 mL of phosphate-buffered saline (PBS) according to their  
123 experimental group and time points (Table 1).

124 Gilts included in this study entered at the DSU splitted into two batches (n=90  
125 each batch) separated by one week. Piglets were ear tagged at birth according to their



126 maternal treatment and cross-fostering was allowed only between sows within the same  
127 treatment. One day prior to weaning, six randomly selected piglets per sow were  
128 monitored and sampled. No antimicrobials against *M. hyopneumoniae* were administrated  
129 to gilts and piglets under study.

130 Study procedures were approved by the Animal Experimentation Ethics  
131 Committee of the Generalitat de Catalunya (*Departament de Territori i Sostenibilitat*,  
132 *Direcció General de Polítiques Ambientals i Medi Natural*; Reference 9336).

#### 133 *2.4. Sample collection and processing*

134 Blood samples and LS were collected from gilts at 1, 14, 27 and 34 wpe, and from 6  
135 piglets of each of them at weaning (Figure 1). Once in the laboratory, blood was  
136 centrifuged at 1500 g for 10 min at 4°C and sera was aliquoted and stored at -20°C until  
137 used. Laryngeal swabs were re-suspended in 1 mL of PBS, vortexed, and stored at -20°C  
138 until DNA extraction was performed.

#### 139 *2.5. Detection of M. hyopneumoniae-specific antibodies in serum*

140 Sera were tested in duplicate for the presence of antibodies against *M. hyopneumoniae* by  
141 means of a commercial competitive ELISA (IDEIA™ *M. hyopneumoniae*, EIA kit,  
142 Oxoid, Thermo Fisher Scientific, UK). ELISA results were expressed as percentage of  
143 inhibition (PI). The PI was calculated considering the mean optical density (OD) of each  
144 sample and the buffer control following the formula: % PI = 100\*(mean sample OD/  
145 mean buffer control OD). Samples with PI < 50% were considered to be positive,  
146 whereas doubtful (PI from 50 to 64%) and negative samples (PI ≥ 65%) were classified as  
147 negative. PI median and ranges of tested samples were calculated.

#### 148 *2.6. DNA extraction and M. hyopneumoniae detection by real time PCR*

149 DNA was extracted from 200 µL of LS suspension using MagMax™ DNA Multi-Sample  
150 Kit (Life Technologies, USA) according to the manufacturer's instructions, on the

151 BioSprint 96 workstation (Qiagen GmbH, Germany). Two different positive extraction  
152 controls were used in each extraction: a LS spiked with *M. hyopneumoniae* strain 11  
153 (ATCC®25095™) and a commercial internal positive control (Xeno™, included in  
154 VetMax™-Plus qPCR Master Mix kit). Negative controls (PBS) were also included to  
155 assess potential contamination during extraction.

156 Extracted DNA was tested by a commercial real time PCR (rt-PCR) for *M.*  
157 *hyopneumoniae* detection: VetMax™-Plus qPCR Master Mix (Life Technologies, USA)  
158 and VetMax™ *M. hyopneumoniae* Reagents (Life Technologies, USA), according to the  
159 manufacturer's instructions. Rt-PCR runs were carried out in ABI PRISM® 7500  
160 machine (Applied Biosystems, Singapore). The rt-PCR threshold was set at 10% of the  
161 maximum fluorescence value of the commercial DNA positive control. Samples with  
162 cycle threshold (Ct) values equal or lower than 40 were considered positive. Ct ranges  
163 were calculated considering only rt-PCR positive samples.

#### 164 2.7. *M. hyopneumoniae* genetic variability

165 Positive rt-PCR LS were genotyped by the Sanger sequencing method and the variable  
166 number of tandem repeats (VNTR) of three loci (p97, p146 and h1) were counted.  
167 Moreover, the reference strain (RF) 11 (ATCC® 25934™) was also included as technique  
168 positive control. Primers used were previously described by Vranckx et al., (2011). These  
169 three loci were individually amplified in a final volume of 50 µL. Reaction mixtures  
170 contained 1X PCR Buffer, 1.5 mM MgCl<sub>2</sub>, 0.2mM each deoxynucleotide triphosphate, 1  
171 µL of each primer, 0.03U/µL U of GoTaq® G2 Flexi DNA Polymerase (Promega,  
172 Madison, USA) and, finally, 6µL of extracted DNA dilution (1:10). Cycling conditions  
173 were 4 min at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 53°C and 30 s at 72°C,  
174 then a final extension step of 7 min at 72°C. The typing PCR products were analysed by  
175 electrophoresis on 2% agarose gel in Tris-Acetate-EDTA (TAE)-buffer and stained with

176 ethidium bromide. These PCR products were purified by ExoSAP-IT® (Isogen Life  
177 Science, The Netherlands) according to manufacturer's instructions and sequenced using  
178 a ABI PRISM 3130xl (Applied Biosystems, Singapore) genetic analyser.

179 Nucleotide sequences were aligned and translated to aminoacid sequences using  
180 FingerPrinting II Informatix software (Applied Maths, Saint-Martens-Latem, Belgium).  
181 VNTR per each locus were counted and a typing variant profile (TP) was assigned  
182 according to the combination of the three loci. The TP was considered different when the  
183 combination of VNTR per each locus was unique. A minimum spanning tree (MST) was  
184 also constructed to visualize the similarity among TP.

## 185 2.8. *Statistical analyses*

186 Bivariate analysis using the Kruskal-Wallis test was applied for median comparison of PI  
187 among gilt groups (A, B, and C) at different sampling points. The homogeneity of PI  
188 values in each group through the study was evaluated by *F* values. The Chi square test  
189 was used to evaluate the proportion of positive rt-PCR samples between treatments at  
190 different sampling points. When significant results were obtained, *a posteriori* contrast  
191 analysis 2 to 2 was performed. *Post hoc* pairwise comparisons were computed using  
192 Tukey's Honestly Significant Difference. Additionally, a linear mixed model was used to  
193 assess the effect of different gilt vaccination programs on piglet colonization and humoral  
194 immunity at weaning, considering sow as a random effect. Statistical analyses were  
195 performed with SAS v9.4 (SAS Institute Inc., Cary, NC, USA). The significance level  
196 was set to  $p < 0.05$ .

197

## 198 **3. Results**

199 *3.1 Detection of antibodies against M. hyopneumoniae in gilts and piglets.*

200 Studied gilts were seronegative at 1 wpe (Table 2, Figure 2). At 14 wpe all gilts with the  
201 exception of one in group C had seroconverted (179/180, 99.4%). By 27 wpe, the number  
202 of gilts were reduced from 180 to 152 (52, 49, and 51 gilts in groups A, B and C,  
203 respectively) since 28 gilts were culled (due to lack of pregnancy and lameness, mainly).  
204 From 146 gilts (49, 47, and 50 gilts in groups A, B and C, respectively) that reached one  
205 week prior to farrowing sampling (34 wpe), all vaccinated gilts (groups A and B)  
206 remained seropositive, whereas the percentage of non-vaccinated seropositive gilts was  
207 slightly lower (44/50, 88.0%). Statistical differences ( $p<0.05$ ) in terms of proportion of  
208 seropositive gilts among vaccinated (A and B) and non-vaccinated (C) groups were  
209 detected at 27 and 34 wpe.

210 Mean PI values ( $\pm$ SD) for each group at different sampling time points are  
211 detailed in Table 2. The PI values were statistically different ( $p<0.05$ ) between  
212 vaccinated (A and B) and non-vaccinated (C) groups at 14, 27 and 34 wpe (Table 2;  
213 Figure 2). Statistical differences ( $p<0.05$ ) among all three groups (A, B and C) were  
214 detected in terms of PI at 14 wpe, showing differences between four and two vaccine  
215 doses. The  $F$  values showed statistical higher homogeneity of IP values (Figure 2)  
216 through this study in vaccinated group A ( $F=1.27$ ) compared to group B ( $F=3.94$ ) and C  
217 ( $F=5.49$ ).

218 A total of 744 piglets (252 from gilts of group A [ $n=42$ ], 252 from gilts of group  
219 B [ $n=42$ ] and 240 from gilts of group C [ $n=40$ ]) born to the 124 gilts that reached  
220 farrowing were sampled one day prior to weaning. The differences in the proportion of  
221 seropositive and PI of piglets from vaccinated and non-vaccinated gilts were statistically  
222 significant. Additionally, a higher number of seropositive piglets coming from gilts from  
223 group A was detected compared to the ones from group B (Table 2). A total of 229  
224 piglets were seronegative (30.8%), where 23 (10%) of them came from seronegative non-

225 vaccinated sows (group C) and the remaining 206 (22 [9.6%], 52 [22.7%] and 132 [57.7  
226 %] from groups A, B and C, respectively) came from seropositive sows (Table 2).

### 227 3.2 *M. hyopneumoniae* detection in LS in gilts and piglets.

228 *M. hyopneumoniae* positive shedding gilts were detected at 14 and 27 wpe (Table 3). The  
229 proportions of rt-PCR positive gilts at 14 wpe in vaccinated groups A (1/60, 1.7%) and B  
230 (2/60, 3.3%) were significantly lower ( $p < 0.05$ ) compared to the non-vaccinated group C  
231 (27/60, 45%). However, no statistical differences were found between vaccinated groups  
232 (A and B) with different number of doses. The proportion of rt-PCR positive gilts was  
233 reduced at 27 wpe and only one positive gilt (1/51, 2.2%) was detected in the group C.  
234 Finally, none of the gilts was positive at 34 wpe for rt-PCR.

235 All LS samples from piglets (n=744) were negative for *M. hyopneumoniae* by rt-  
236 PCR.

### 237 3.3 Characterization of *M. hyopneumoniae* genotypes through the study

238 All rt-PCR positive samples detected into previous batches (FS1=10 and FS2=19), 14  
239 wpe (n=1 in group A, n=2 in group B and n=27 in group C) and 27 wpe (n=1 in group C)  
240 were used for *M. hyopneumoniae* genetic characterization. From these 50 samples, 43  
241 (86.0%) were successfully sequenced by the three selected loci (Table 4). Eleven  
242 different genotypes were detected among samples. Five TP were detected in each batch  
243 FS1 (n=20) and FS2 (n=19), although two variants (TP4 and TP5) were identified in both  
244 batches. Three variants were detected at 14 wpe, being different from those detected in  
245 previous batches (Table 4). No TP was able to be characterized from the positive gilt  
246 from group A at 14 wpe. A minimum spanning tree was generated to show the genetic  
247 variation over time (Figure 3).

248 Regarding VNTR per each locus, the P97 locus showed limited heterogeneity due to  
249 the fact that only two VNTR (9 and 11 repeats) were identified (Table 4). The P146 locus

250 showed higher variability at FS1 and FS2, ranging from 38 to 47 and from 22 to 47  
251 repeats, respectively. The VNTR of P146 at 14 wpe was homologous (20 repeats) in all  
252 identified variants. For locus H1, the VNTR varied from 4 to 7 repeats.

253

#### 254 **4. Discussion**

255 One of the key points to control EP within farms is the *M. hyopneumoniae* transmission  
256 between the dam and her piglets. Since gilts are considered the main *M. hyopneumoniae*  
257 shedders, acclimation strategies focused on reducing the bacterial shedding at first  
258 farrowing have been proposed (Pieters and Fano, 2016). Vaccination has been determined  
259 as the most used strategy for acclimation as well as elimination, although different  
260 number of doses and application timings are being used (Garza-Moreno et al., 2018).  
261 However, its effect on gilt shedding, humoral immune response, as well as the maternal  
262 derived immunity transfer to piglets was not assessed in any of those studies. The number  
263 of vaccine doses and the application timing that has been proposed in the past has been 2  
264 doses at 1 and 3 wpe to GDU (Yeske, 2007), or 3 doses at 55 and 220 days of age of gilts,  
265 and another last dose 2 weeks prior to farrowing (Alfonso et al., 2004). On the other  
266 hand, the effect of sow vaccination against *M. hyopneumoniae* infection at 8 and 4  
267 (Grosse Beilage and Schreiber, 2005), or 5 and 3 weeks prior to farrowing (Ruiz et al.,  
268 2003; Sibila et al., 2008) has been evaluated. All the three studies agreed that sow  
269 vaccination against *M. hyopneumoniae* enhanced levels of antibodies in vaccinated sows  
270 as well as in their piglets. In addition, Ruiz *et al.* (2003) and Sibila *et al.* (2008)  
271 concluded that sow vaccination could reduce, numerically, the prevalence of piglet  
272 colonization, whereas Grosse-Beilage and Schreiber (2005) did not evaluate this  
273 parameter. Therefore, the objective of the present study was to evaluate the effect of gilt

274 vaccination against *M. hyopneumoniae* using different vaccination programs during the  
275 acclimation period on gilt shedding, and consequently, on piglet's colonization.

276         The current study used vaccination protocols based on multiple doses (four and  
277 two) since a number of field studies have hypothesized that a high number of vaccine  
278 doses could induce a strong immune response, reduce colonization, and better control the  
279 disease (Alfonso et al., 2004; Yeske, 2007). The interval between the first and booster  
280 vaccination in the present study was 2 weeks to complete the vaccination protocol within  
281 a rather usual timing of acclimation at GDU (Garza-Moreno et al., 2017). In order to  
282 minimize the effect of the previous humoral immune status, gilts were distributed into  
283 three groups according to ELISA PI values at entry. At 14 wpe, all vaccinated gilts had  
284 seroconverted, as expected with commercial vaccines. From the non-vaccinated group, all  
285 gilts but one also seroconverted, indicating that *M. hyopneumoniae* natural exposure  
286 occurred soon after entry. Significant differences of humoral responses in terms of PI  
287 were detected between vaccinated and non-vaccinated groups at all sampling points, as  
288 previously described by Kristensen et al. (2004) in sows. Interestingly, all vaccinated gilts  
289 remained seropositive during all study duration. On the contrary, the proportion of  
290 seropositive gilts in the non-vaccinated group decreased slightly over time (from 98% at  
291 1 wpe to 88% in both 27 and 34 wpe). These findings suggest that vaccination may  
292 provide a longer duration of humoral immunity compared to that of natural infection.  
293 Furthermore, the statistically significant differences found between animals vaccinated  
294 with four or two vaccine doses at 14 wpe suggests that repeated vaccination elicited  
295 stronger immune response (lower PI). Indeed, PI values from vaccinated gilts with four  
296 doses remained statistically more homogeneous (lower *F* values) than those vaccinated  
297 with two doses followed by the non-vaccinated group, suggesting that vaccination helped  
298 homogenizing the immune status of the studied population.

299 A significantly higher percentage of seropositive piglets at weaning from gilts  
300 vaccinated four or two times was detected compared to those from non-vaccinated gilts.  
301 This finding is in agreement with other studies in sows (Kristensen et al., 1981; Grosse  
302 Beilage and Schereiber, 2005), fitting with the hypothesis that vaccinated gilts show  
303 higher antibody levels against *M. hyopneumoniae* (lower PI) than non-vaccinated gilts in  
304 colostrum. Nevertheless, no statistical differences were identified between piglets coming  
305 from gilts from groups A and B, suggesting the passive humoral transfer might be fairly  
306 independent of 2 or 4 doses applied. Additionally, 206 seronegative piglets were from  
307 seropositive sows at 34 wpe. This fact could be explained by a poor colostrum intake  
308 (Quesnel, 2011) and/or the decay of *M. hyopneumoniae* maternal antibodies since  
309 previous studies reported a median half-life of maternally derived antibodies of 15 days  
310 and, therefore, the amount of transferred antibodies was dependent on the dam's  
311 serological status (Morris et al., 1995).

312 *M. hyopneumoniae* shedding was first detected at 14 wpe, with the proportion of  
313 shedding gilts significantly lower in the vaccinated than in non-vaccinated groups. This  
314 finding could be associated with the reduction of *M. hyopneumoniae* bacterial load by  
315 vaccination, as previously reported by Woolley et al. (2014). Moreover, an absolute  
316 reduction of shedding gilts was detected at 27 wpe in vaccinated groups, and only one  
317 non-vaccinated gilt was a shedder. *M. hyopneumoniae* was not detected in any studied  
318 group at 34 wpe. The fact that all gilts from the non-vaccinated group seroconverted  
319 indicates that *M. hyopneumoniae* infection occurred, and this probably took place in a  
320 relatively short period of time, since by 27 wpe only one gilt was detected as PCR  
321 positive. Taking this into account, gilts from this trial could have been naturally exposed  
322 to *M. hyopneumoniae* around 9-12 wpe, shortly after mixing them with the positive own  
323 replacement. The peak of shedding might have been reached at 14 wpe (5 weeks after this



324 exposure) and the complete cease of shedding would have occurred between 27 and 34  
325 wpe (18-25 weeks after exposure). The duration of gilt shedding in this study seemed to  
326 be shorter compared to a previous study that detected shedders up to 200 days post-  
327 infection under experimental conditions (Pieters et al., 2009). The difference in the  
328 duration of shedding may be explained by the lower *M. hyopneumoniae* load in naturally  
329 infected gilts under field conditions compared to experimental conditions, where the  
330 bacterial load administered endo-tracheally might be much higher. Moreover, given the  
331 limited number of samplings over time of this study, the proposed timings about *M.*  
332 *hyopneumoniae* infection dynamics within this breeding herd should be considered as an  
333 estimation. Further research is needed to gain insight into infection dynamics of gilts  
334 under field conditions.

335         Previous studies have suggested that *M. hyopneumoniae* piglet colonization at  
336 weaning is correlated with respiratory disease and lung lesions at fattening stages (Fano  
337 et al., 2007; Sibila et al., 2007). However, in the present field study, *M. hyopneumoniae*  
338 gilt shedding one week prior to farrowing (34 wpe) was not detected by rt-PCR and all  
339 piglets from vaccinated and non-vaccinated gilts were rt-PCR negative. Thus, association  
340 between gilt shedding at farrowing and piglet colonization at weaning could not be  
341 assessed. Obtained results are in agreement with previous studies with similar *M.*  
342 *hyopneumoniae* infection dynamics in which piglets were also negative at weaning  
343 (Takeuti et al., 2017a, 2017b).

344         Taking all these results together, the usage of two or four vaccination dose  
345 protocols in gilts seemed to be effective strategies for decreasing *M. hyopneumoniae*  
346 shedding and infectious pressure within a farm. Furthermore, results using four doses  
347 were slightly better (from a numeric point of view) than using two doses regarding  
348 ELISA results. Notwithstanding, these differences were only statistically significant in

349 terms of PI at 14 wpe, suggesting that vaccination with these two extra doses is not  
350 apparently justified from an infection and seroconversion points of view. Moreover,  
351 further studies are needed to compare these two doses with one dose.

352 The intra-farm genetic diversity of *M. hyopneumoniae* has been previously  
353 described using different methods and bacterium loci and thus, results are diverse.  
354 Several studies described a high intra-farm genetic diversity (Stakenborg., 2006; Nathues  
355 et al., 2011; dos Santos et al., 2015; Tamiozzo et al., 2015; Michiels et al., 2017; Takeuti  
356 et al., 2017a) whereas others concluded that the variability was limited within the same  
357 farm (Stakenborg et al., 2005; Mayor et al., 2007, 2008; Vranckx et al., 2012; Charlebois  
358 et al., 2014; Galina-Pantoja L. et al., 2016). Results from the current study showed high  
359 *M. hyopneumoniae* variability within the farm. In the previous gilts batches (FS1 and  
360 FS2), higher variability was detected compared to monitored gilts at 14 wpe. Despite  
361 variants being different, similarity between TP 8 from FS2 and the more prevalent variant  
362 at 14 wpe (TP 10) might indicate that TP 10 was the result of mutations for each loci  
363 along this study. These findings are in agreement with previous reports that concluded  
364 that Mollicutes can exhibit high mutation and recombination rates by modification of  
365 environmental conditions (Razin et al., 1998). Furthermore, this similarity also suggests  
366 that the source of infection of gilts included in the study at entry was the own  
367 replacement (infected already based on data from FS1 and FS2) located in the same  
368 GDU. Unfortunately, information about *M. hyopneumoniae* variants harboured by own  
369 replacement over time was not assessed in the present study. Finally, analysing the  
370 VNTR obtained per locus, results of P97 and P146 loci are in accordance with previously  
371 published reports in which Spanish *M. hyopneumoniae* strains showed approximately 20  
372 repeats in P97 and more than 30 repeats in P146 (dos Santos et al., 2015). No previous  
373 data regarding VNTR for H1 are available.

374 In conclusion, the present study showed that *M. hyopneumoniae* gilt vaccination at  
375 acclimation period significantly reduced the *M. hyopneumoniae* shedding of gilts at 14  
376 wpe and increased antibody levels (low PI) of dams and their piglets. Since *M.*  
377 *hyopneumoniae* shedding in gilts was not detected at 34 wpe, the lack of bacterial piglet  
378 colonization was expectable. Despite the fact that *M. hyopneumoniae* vaccination does  
379 not provide full protection, the infectious pressure within the gilt population of the  
380 studied herd was significantly reduced. Gilt vaccination protocol with four doses showed  
381 slightly better numerical results than the protocol with two doses during all study.  
382 Therefore, these results suggested that the vaccination with two doses seems to be  
383 sufficient to reduce the infectious pressure and to induce strong and humoral immune  
384 response in gilts. Based on obtained results, a higher number of vaccine doses does not  
385 seem to be justified. Finally, the characterization of *M. hyopneumoniae* strains confirmed  
386 high genetic variability of this bacterium within the studied farm.  
387

388 **Conflicts of interest**

389 Laura Garza-Moreno, Roman Krejci, and Marta Carmona are employees of Ceva Santé  
390 Animale.

391

392 **Funding**

393 This work was funded by Ceva Santé Animale, Secretaria d'Universitats i Recerca del  
394 Departament d'Economia i Coneixement de la Generalitat de Catalunya (2015DI078).

395 The funding from CERCA Programme (*Generalitat de Catalunya*) to IRTA is also  
396 acknowledged.

397

398 **Acknowledgments**

399 The authors would like to thank Raúl Cuadrado, Patricia Pleguezuelos, Diego Pérez, Rosa  
400 López, Gemma Guevara, Eva Huerta, Anna Llorens and the farm personnel for their  
401 collaboration and support in the study.

## **Tables**

**Table 1.** Vaccination schedules against *M. hyopneumoniae* performed during the gilt acclimation period.

<b>Group name</b>	<b>No. of gilts</b>	<b>Vaccine doses</b>	<b>Vaccination schedule</b>			
			2 wpe	4 wpe	6 wpe	8 wpe
A	60	4	Hyogen®	Hyogen®	Hyogen®	Hyogen®
B	60	2	Hyogen®	PBS	Hyogen®	PBS
C	60	0	PBS	PBS	PBS	PBS

wpe: weeks post-entry; PBS: phosphate-buffered saline

**Table 2.** Proportion (%) of *M. hyopneumoniae* seropositive gilts and piglets and median (range) of percentage of inhibition (PI) at different sampling points.

Groups	Sampling points									
	1 wpe		14 wpe		27 wpe		Prefarrowing (34 wpe)		Piglets (at weaning)	
	Prop (%)	PI (Range)	Prop (%)	PI (Range)	Prop (%)	PI (Range)	Prop (%)	PI (Range)	Prop (%)	PI (Range)
A	0/60 0% <sup>a</sup>	67.1 (51.2-89.4) <sup>a</sup>	60/60 100% <sup>a</sup>	4.8 (3.1-19.8) <sup>a</sup>	52/52 100% <sup>a</sup>	6.8 (3.4-39.3) <sup>a</sup>	49/49 100% <sup>a</sup>	5.7 (3.6-17.8) <sup>a</sup>	230/252 91% <sup>a</sup>	15.5 (2.1-98.7) <sup>a</sup>
B	0/60 0% <sup>a</sup>	67.1 (50.6-85.5) <sup>a</sup>	60/60 100% <sup>a</sup>	5.5 (3.7-13.5) <sup>b</sup>	49/49 100% <sup>a</sup>	8.07 (2.8-22.4) <sup>a</sup>	47/47 100% <sup>a</sup>	6.2 (4.0-36.6) <sup>a</sup>	200/252 79% <sup>a</sup>	23.9 (2.0-94.3) <sup>a</sup>
C	0/60 0% <sup>a</sup>	66.9 (50.4-85.2) <sup>a</sup>	59/60 98% <sup>a</sup>	14.3 (3.3-53.2) <sup>c</sup>	45/51 88% <sup>b</sup>	31.7 (6.6-82.1) <sup>b</sup>	44/50 88% <sup>b</sup>	28.7 (5.0-61.8) <sup>b</sup>	85/240 35% <sup>b</sup>	27.3 (1.0-99.0) <sup>b</sup>
Total	0/180	-	179/180 (99.4)	-	146/152 (96.1)	-	140/146 (95.9)	-	515/744 (69.2)	-

wpe: week post-entry; Prop: Proportion; Range: minimum-maximum; Different superscripts within each column indicate significant differences among groups at different time points ( $p < 0.05$ ).

**Table 3.** Proportion (%) of *M. hyopneumoniae* rt-PCR positive gilts and piglets and Ct values at different sampling points of the study.

Groups	Sampling points									
	1 wpe		14 wpe		27 wpe		Prefarrowing (34 wpe)		Piglets (at weaning)	
	Prop (%)	Ct range (Max – Min)	Prop (%)	Ct range (Min– Max)	Prop (%)	Ct range (Max – Min)	Prop (%)	Ct range (Max – Min)	Prop (%)	Ct range (Max – Min)
A	0/60 0% <sup>a</sup>	NA	1/60 2% <sup>a</sup>	38.8-38.8 <sup>a</sup>	0/52 0% <sup>a</sup>	NA	0/49 0% <sup>a</sup>	NA	0/252 0% <sup>a</sup>	NA
B	0/60 0% <sup>a</sup>	NA	2/60 3% <sup>a</sup>	32.2-37.8 <sup>a</sup>	0/49 0% <sup>a</sup>	NA	0/47 0% <sup>a</sup>	NA	0/252 0% <sup>a</sup>	NA
C	0/60 0% <sup>a</sup>	NA	27/60 45% <sup>b</sup>	29-1-38.7 <sup>a</sup>	1/51 2% <sup>a</sup>	37.5-37.5	0/50 0% <sup>a</sup>	NA	0/240 0% <sup>a</sup>	NA

*wpe*: week post-entry; *Prop*: Proportion; *Na*: Non-applicable; Different superscript within each column indicate significant differences among groups ( $p < 0.05$ ). Ct range has been calculated considering only rt-PCR positive animals.


**Table 4.** Variable number of tandem repeat (VNTR) profiles and typing profile (TP) in *M. hyopneumoniae* positive gilts using three loci.

Sampling point	Number of gilts carrying the variant (%)	VNTR			TP	Group	
		P97	P146	H1		Treatment	n
FS1	1 (2.3)	11	38	6	1	NA	10
	1 (2.3)	11	42	6	2		
	2 (4.5)	11	45	6	3		
	5 (11.3)	11	46	6	4		
	1 (2.3)	11	47	6	5		
FS2	1 (2.3)	11	22	4	6	NA	9
	1 (2.3)	11	43	6	7		
	5 (11.3)	11	46	6	4		
	1 (2.3)	11	47	6	5		
	1 (2.3)	9	22	6	8		
14 wpe	1 (2.3)	9	20	4	9	C	1
	19 (43.2)	9	20	6	10	B	2
						C	17
						C	4
RF	4 (9.0)	9	20	7	11	C	4
RF	1 (2.3)	14	21	10	RF	NA	1
<b>Total</b>	<b>44 (100.0)</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>12</b>	<b>NA</b>	<b>44</b>


TP: Typing profile assigned; *wpe*: week post-entry; RF: Reference strain; NA: Non-applicable.



## Figures




**Figure 1.** Study design, housing location and sampling points of gilts and piglets included in the study. Housing sites are gilt development unit (GDU), detection and synchronization unit (DSU), gestation unit (GU) and farrowing unit (FU). Shapes represent gilt vaccination (▲) and sampling points of gilts (●) at different weeks post-entry (wpe) into GDU indicated by numbers. Additionally, piglets (◆) were sampled at weaning (equivalent to 38 wpe of gilts).



1

2 **Figure 2.** Percentages of inhibition (%) of gilts from groups A (■), B (■) and C (■) at 1, 14, 27  
 3 and 34 wpe; and from their piglets at weaning. Statistically significant differences ( $p < 0.05$ ) were  
 4 observed between vaccinated (A and B) and non-vaccinated groups (C) (\*) as well as among all  
 5 three groups (\*\*). The discontinuous line represents ELISA seropositivity threshold.

6



7

8 **Figure 3.** Minimum spanning tree showing different *M. hyopneumoniae* variant profiles detected.  
 9 RF: Reference strain 11 used as technique control. Each circle represents a variant profile. The  
 10 size of the circle is proportional with the number of samples belonging to each variant profile.  
 11 Absolute distances among variant profiles are represented by link label.

12

13

14

15 **References**

- 16 Alfonso, A., Geiger, J., Feixes, C., Fonz, J., Torremorell, M., 2004. *Mycoplasma*  
17 *hyopneumoniae* and PRRSV elimination in a 1700 sows multi-site system. In:  
18 Proceedings of the 18th IPVS Congress, Hamburg, Germany. pp. 174.
- 19 Boonsoongnern, A., Jirawattanapong, P., Lertwatcharasarakul, P., 2012. The Prevalence  
20 of *Mycoplasma hyopneumoniae* in Commercial Suckling Pigs in Thailand. *World J.*  
21 *Vaccines* 2, 161–163.
- 22 Charlebois, A., Marois-Créhan, C., Hélie, P., Gagnon, C.A., Gottschalk, M.,  
23 Archambault, M., 2014. Genetic diversity of *mycoplasma hyopneumoniae* isolates of  
24 abattoir pigs. *Vet. Microbiol.* 168, 348–356.
- 25 dos Santos, L.F., Sreevatsan, S., Torremorell, M., Moreira, M.A.S., Sibila, M., Pieters,  
26 M., 2015. Genotype distribution of *Mycoplasma hyopneumoniae* in swine herds from  
27 different geographical regions. *Vet. Microbiol.* 175, 374–381.
- 28 Fano, E., Pijoan, C., Dee, S., Deen, J., 2007. Effect of *Mycoplasma hyopneumoniae*  
29 colonization at weaning on disease severity in growing pigs. *Can. J. Vet. Res.* 71, 195–  
30 200.
- 31 Fano, E., Payne, B., 2015. *Mycoplasma hyopneumoniae* gilt acclimation and sow herd  
32 stability: Essentials to the systematic control - approach In: AASV Annual Meeting.  
33 Orlando, Florida. pp. 175–178.
- 34 Galina-Pantoja L., Pettit, K., Dos Santos, L.F., Tubbs, R., Pieters, M., 2016. *Mycoplasma*  
35 *hyopneumoniae* genetic variability within a swine operation. *J. Vet. Diagn. Invest.* 28,  
36 175–179.
- 37 Garza-Moreno, L., Segalés, J., Pieters, M., Romagosa, A., Sibila, M., 2017. Survey on  
38 *Mycoplasma hyopneumoniae* gilt acclimation practices in Europe. *Porcine Health Manag.*  
39 3, 21.

40 Garza-Moreno, L., Segalés, J., Pieters, M., Romagosa, A., Sibila, M., 2018. Acclimation  
41 strategies in gilts to control *Mycoplasma hyopneumoniae* infection. *Vet. Microbiol.* 219,  
42 23–29.

43 Grosse Beilage and Schreiber, 2005. Grosse Beilage and Schreiber (2005). *Dtsch*  
44 *Tierarztl Wochenschr.* 112, 256–61.

45 Kristensen, B., Paroz, P., Nicolet, J., Wanner, W., de Weck, A., 1981. Cell-mediated and  
46 humoral immune response in swine after vaccination and natural infection with  
47 *Mycoplasma hyopneumoniae*. *Am J Vet Res.* 42, 784–8.

48 Kristensen, C.S., Andreasen, M., Ersboll, A.K., Nielsen, J.P., 2004. Antibody response in  
49 sows and piglets following vaccination against *Mycoplasma hyopneumoniae*, toxigenic  
50 *Pasteurella multocida*, and *Actinobacillus pleuropneumoniae*. *Can. J. Vet. Res.* 68, 66–  
51 70.

52 Maes, D., Verdonck, M., Deluyker, H., de Kruif, A., 1996. Enzootic pneumonia in pigs.  
53 *Vet. Q.* 18, 104–109.

54 Mayor, D., Jores, J., Korczak, B.M., Kuhnert, P., 2008. Multilocus sequence typing (   
55 MLST ) of *Mycoplasma hyopneumoniae* : A diverse pathogen with limited clonality. *Vet.*  
56 *Microbiol.* 127, 63–72.

57 Mayor, D., Zeeh, F., Frey, J., Kuhnert, P., 2007. Diversity of *Mycoplasma*  
58 *hyopneumoniae* in pig farms revealed by direct molecular typing of clinical material. *Vet.*  
59 *Res.* 38, 391–398.

60 Michiels, A., Vranckx, K., Piepers, S., Del Pozo Sacristán, R., Arsenakis, I., Boyen, F.,  
61 Haesebrouck, F., Maes, D., 2017. Impact of diversity of *Mycoplasma hyopneumoniae*  
62 strains on lung lesions in slaughter pigs. *Vet. Res.* 48, 2, 1-14.

63 Morris, C.R., Gardner, I.A., Hietala, S.K., Carpenter, T.E., Anderson, R.J., Parker, K.M.,  
64 1995. Seroepidemiologic study of natural transmission of *Mycoplasma hyopneumoniae*

65 in a swine herd. *Prev. Vet. Med.* 21, 323–337.

66 Nathues, H., Beilage, E. grosse, Kreienbrock, L., Rosengarten, R., Spergser, J., 2011.

67 RAPD and VNTR analyses demonstrate genotypic heterogeneity of *Mycoplasma*

68 *hyopneumoniae* isolates from pigs housed in a region with high pig density. *Vet.*

69 *Microbiol.* 152, 338–345.

70 Pieters, M., Pijoan, C., Fano, E., Dee, S., 2009. An assessment of the duration of

71 *Mycoplasma hyopneumoniae* infection in an experimentally infected population of pigs.

72 *Vet. Microbiol.* 134, 261–266.

73 Pieters, M., Fano, E., 2016. *Mycoplasma hyopneumoniae* management in gilts. *Vet. Rec.*

74 178 (122), 1-123. doi:10.1136/vr.i481

75 Quesnel, H., 2011. Colostrum production by sows: Variability of colostrum yield and

76 immunoglobulin G concentrations. *Animal* 5, 1546–1553.

77 Razin, S., Yogeve, D., Naot, Y., 1998. Molecular biology and pathogenicity of

78 mycoplasmas. *Microbiol. Mol. Biol. Rev.* 62, 1094–156.

79 Ruiz, A., Utrera, V., Pijoan, C., 2003. Effect of *Mycoplasma hyopneumoniae* sow

80 vaccination piglet colonization at weaning. *J Swine Health Prod* 11, 131–134.

81 Sibila, M., Nofrarías, M., López-Soria, S., Segalés, J., Riera, P., Llopart, D., Calsamiglia,

82 M., 2007. Exploratory field study on *Mycoplasma hyopneumoniae* infection in suckling

83 pigs. *Vet. Microbiol.* 121, 352–356.

84 Sibila, M., Bernal, R., Torrents, D., Riera, P., Llopart, D., Calsamiglia, M., Segalés, J.,

85 2008. Effect of sow vaccination against *Mycoplasma hyopneumoniae* on sow and piglet

86 colonization and seroconversion, and pig lung lesions at slaughter. *Vet. Microbiol.* 127,

87 165–170.

88 Stakenborg, T., Vicca, J., Butaye, P., Maes, D., Peeters, J., De Kruif, A., Haesebrouck, F.,

89 2005. The diversity of *Mycoplasma hyopneumoniae* within and between herds using

90 pulsed-field gel electrophoresis. *Vet. Microbiol.* 109, 29–36.

91 Stakenborg, T., Vicca, J., Maes, D., Peeters, J., de Kruif, A., Haesebrouck, F., Butaye, P.,  
92 2006. Comparison of molecular techniques for the typing of *Mycoplasma*  
93 *hyopneumoniae* isolates. *J. Microbiol. Methods* 66, 263–275.

94 Takeuti, K.L., de Barcellos, D.E.S.N., de Andrade, C.P., de Almeida, L.L., Pieters, M.,  
95 2017a. Infection dynamics and genetic variability of *Mycoplasma hyopneumoniae* in self-  
96 replacement gilts. *Vet. Microbiol.* 208, 18–24.

97 Takeuti, K.L., de Barcellos, D.E.S.N., de Lara, A.C., Kunrath, C.F., Pieters, M., 2017b.  
98 Detection of *Mycoplasma hyopneumoniae* in naturally infected gilts over time. *Vet.*  
99 *Microbiol.* 203, 215–220.

100 Tamiozzo, P., Zamora, R., Lucchesi, P.M.A., Estanguet, A., Parada, J., Carranza, A.,  
101 Camacho, P., Ambrogi, A., 2015. MLVA typing of *Mycoplasma hyopneumoniae*  
102 bacterins and field strains. *Vet. Rec. Open* 2:e000117. doi:10.1136/vetreco-2015-000117

103 Thacker, E.L., Minion, F.C., 2012. Mycoplasmosis. In: Zimmerman, J.J., Karriker, L.A.,  
104 Schwartz, K.J. (Eds.), *Diseases of swine*, 10th ed. Wiley-Blackwell, Oxford, UK pp.779-  
105 797.

106 Vranckx, Maes, D., Calus, D., Villarreal, I., Pasmans, F., Haesebrouck, F., 2011.  
107 Multiple-locus variable-number tandem-repeat analysis is a suitable tool for  
108 differentiation of *Mycoplasma hyopneumoniae* strains without cultivation. *J Clin*  
109 *Microbiol.* 49, 2020–2023. doi:10.1128/JCM.00125-11

110 Vranckx, K., Maes, D., Sacristán, R.D.P., Pasmans, F., Haesebrouck, F., 2012. A  
111 longitudinal study of the diversity and dynamics of *Mycoplasma hyopneumoniae*  
112 infections in pig herds. *Vet. Microbiol.* 156, 315–321.

113 Woolley, L.K., Fell, S.A., Gonsalves, J.R., Raymond, B.B.A., Collins, D., Kuit, T.A.,  
114 Walker, M.J., Djordjevic, S.P., Eamens, G.J., Jenkins, C., 2014. Evaluation of

115 recombinant *Mycoplasma hyopneumoniae* P97/P102 paralogs formulated with selected  
116 adjuvants as vaccines against mycoplasmal pneumonia in pigs. *Vaccine* 32, 4333–4341.  
117 Yeske, P., 2007. *Mycoplasma* eradication strategies. In: AASV Annual Meeting.  
118 Orlando, Florida. pp. 367–370.